Skip to main content
. 2014 Apr;349(1):118–125. doi: 10.1124/jpet.113.210203

Fig. 4.

Fig. 4.

(A) The response to carbachol (CCh) in the presence of the treatments as a percentage of the initial response (mean ± SEM, n = 24–29). (B) With the 5-LO inhibitor zileuton present to prevent cysLT synthesis, exposure to GSK1016790 (100 nM, ○) does not alter the concentration-response relationship between exogenously applied LTD4 concentration-response curves for human bronchial contractions (n = 4 donors), or in the LTE4 concentration-response curves (n = 2 donors) (C).

HHS Vulnerability Disclosure